New York, New York-- (Newsfile Corp. - February 7, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Novo Nordisk (NYSE: NVO) and certain ...

JPMorgan lowered the firm’s price target on Novo Nordisk (NVO) to DKK 1,000 from DKK 1,050 and keeps an Overweight rating on the ...

Finally, some good news for Novo Nordisk (NYSE: NVO) shareholders! Twice in the past two months, the Danish manufacturer of GLP-1 drugs for weight loss and diabetes treatment has reported clinical ...

Novo Nordisk is facing serious pressure from a powerful adversary. It still has plenty of leeway to penetrate its target market, for now. Investors should keep a close eye on this company.

With nearly $14 billion in sales in 2023, it shows no signs of slowing down, much to the delight of its Danish manufacturer, Novo Nordisk A/S (NYSE: NVO). A Scandinavian economic behemoth ...

Denmark and its self-ruling territory of Greenland have caught the eye of Donald Trump. © 2024 Fortune Media IP Limited. All Rights Reserved. Use of this site ...

Medicare is preparing to negotiate prices on GLP-1 drugs such as Ozempic. Novo Nordisk investors could see the news put $14.3 billion in Medicare revenue at risk. Viking Therapeutics stock ...

In the ongoing quest to expand semaglutide’s clinical pedigree and cement the GLP-1's market position, Novo Nordisk is rolling out new data on a higher-dose injection in obesity. In the phase 3b ...

On Friday, Guggenheim Securities adjusted its financial outlook for Novo Nordisk (NYSE:NVO) shares (NOVOB:DC) (NYSE: NVO), raising the price target slightly to DKK798.00 from DKK795.00.

Novo Nordisk, Other Firms Meet Danish PM to Discuss Trump Tariff Threats COPENHAGEN (Reuters) - Danish businesses are concerned about a possible trade conflict with the United States over ...

Among business leaders in the meeting were Lars Fruergaard Jorgensen, CEO of Novo Nordisk (NOVOb.CO), opens new tab, which generates more than half of its sales in the United States. Novo ...

I’m cautious about Novo Nordisk's stock in the short term due to the recent selloff momentum, which could bottom out if the FDA rejects its petition to restrict compounding alternatives.